MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6), also known as MEKK6, is a serine/threonine protein kinase that functions as an upstream activator of the p38 MAPK signaling pathway[1]. It plays crucial roles in cellular stress responses, inflammation, brain development, and neurodegeneration[2]. As a MAP3K, MEKK6 sits at a critical node in the stress-activated protein kinase (SAPK) cascade, translating extracellular and intracellular stress signals into cellular responses through selective activation of p38 MAPK isoforms[3].
The p38 MAPK pathway is one of the major mitogen-activated protein kinase cascades in eukaryotic cells, alongside the JNK and ERK pathways. While ERK is primarily activated by growth factors and mitogens, p38 and JNK are strongly activated by cellular stresses including oxidative stress, cytokine exposure, UV radiation, and endotoxin stimulation. MEKK6's primary function is to specifically activate the MKK3/MKK6-p38 pathway, making it a key regulator of stress-induced cellular responses[4].
| MAP3K6 Gene Summary | |
|---|---|
| Gene Symbol | MAP3K6 |
| Full Name | Mitogen-Activated Protein Kinase Kinase Kinase 6 |
| Aliases | MEKK6, MAPKKK6, MAP3K6 |
| Chromosomal Location | 1p36.21 |
| NCBI Gene ID | [9064](https://www.ncbi.nlm.nih.gov/gene/9064) |
| OMIM ID | [603170](https://www.omim.org/entry/603170) |
| Ensembl ID | ENSG00000142733 |
| UniProt ID | [O43283](https://www.uniprot.org/uniprot/O43283) |
| Gene Type | Protein coding |
| Associated Diseases | Parkinson's Disease, Alzheimer's Disease, ALS, Neuroinflammation, Cancer |
MEKK6 is a 372-amino acid serine/threonine protein kinase with a modular domain structure that enables its role as a signaling scaffold and kinase activator. The protein contains several functional domains that mediate its unique functions in the p38 MAPK pathway.
| Domain | Position | Function |
|---|---|---|
| N-terminal Regulatory Domain | 1-90 aa | Auto-inhibitory region, maintains inactive conformation |
| Kinase Catalytic Domain | 91-277 aa | Ser/Thr protein kinase activity, ATP binding |
| C-terminal Scaffold Domain | 278-372 aa | Protein-protein interactions, complex assembly |
MEKK6 exhibits substrate specificity for the MAP2Ks MKK3 and MKK6, which are its primary phosphorylation targets[4:1]. Unlike other MAP3K family members, MEKK6 shows strong preference for MKK3/MKK6 over other MAP2Ks, making it a dedicated activator of the p38 MAPK branch. The kinase activity is regulated by:
The p38 MAPK pathway is one of the major stress-activated protein kinase cascades in mammalian cells. MEKK6 serves as a dedicated upstream activator of this pathway[3:1]:
Stress Signals → MEKK6 → MKK3/MKK6 → p38 MAPK → Cellular Responses
The pathway responds to various cellular stresses:
MEKK6 can activate multiple p38 MAPK isoforms with different tissue distributions and functions[5]:
| Isoform | Brain Expression | Primary Functions |
|---|---|---|
| p38α | Ubiquitous | Inflammatory responses, stress adaptation |
| p38β | Brain, heart | Neuronal survival, stress tolerance |
| p38γ | Skeletal muscle, brain | Synaptic plasticity, muscle function |
| p38δ | Lung, kidney | Tissue-specific stress responses |
MEKK6 functions within the broader mitogen-activated protein kinase (MAPK) signaling network, which coordinates cellular responses to diverse environmental stimuli. The three major MAPK cascades in mammals are:
MEKK6 exhibits selectivity for the p38 branch, with minimal activation of ERK or JNK pathways[3:2]. This specificity is mediated by:
The MEKK6-p38 pathway interacts with multiple other signaling pathways:
| Pathway | Interaction Type | Functional Consequence |
|---|---|---|
| NF-κB | Cross-inhibition | p38 inhibits NF-κB transcriptional activity |
| JNK | Sequential activation | p38 can activate JNK pathway members |
| PI3K/Akt | Negative regulation | Akt phosphorylates and inhibits p38 |
| mTOR | Complex regulation | p38 can both activate and inhibit mTOR |
| Wnt/β-catenin | Bidirectional | Pathway cross-talk affects gene expression |
Once activated, p38 MAPK phosphorylates numerous transcription factors that execute gene expression programs:
Through these transcription factors, MEKK6-p38 signaling controls:
MEKK6 interacts with multiple proteins to execute its signaling functions:
| Protein | Interaction Domain | Functional Significance |
|---|---|---|
| MKK3 | Kinase domain | Direct phosphorylation substrate |
| MKK6 | Kinase domain | Direct phosphorylation substrate |
| MEKK3 | C-terminal domain | Forms heterodimeric complex |
| TAK1 | C-terminal domain | Upstream activation |
| TAB1/2 | C-terminal domain | TAK1 complex subunits |
| Hsp90 | Multiple domains | Molecular chaperone |
| 14-3-3 proteins | Regulatory domain | Restricts signaling |
The p38 MAPK phosphorylates numerous substrate proteins:
| Substrate | Phosphorylation Site | Cellular Function |
|---|---|---|
| MAPKAPK2 | T222, S272 | Kinase that phosphorylates H3, HSP27 |
| MSK1/2 | Multiple sites | Nucleosomal kinase, transcription |
| MK2/3 | T334, S338 | Cytokine production, actin dynamics |
| MNK1/2 | Multiple sites | Translation initiation |
The p38 MAPK pathway is activated in PD models and patient brains, with MEKK6 playing a central role in dopaminergic neuron degeneration[6]. Evidence indicates:
Recent studies have demonstrated that MEKK6-p38 signaling is a key mediator of oxidative stress-induced dopaminergic neuron death, with inhibition providing neuroprotection in preclinical models[9][10]. Targeting the MEKK6-p38 axis represents a promising therapeutic strategy for PD.
In Alzheimer's disease, the MEKK6-p38 pathway contributes to multiple aspects of pathogenesis[11]. Neuroinflammation is a key driver of AD progression, with MEKK6-p38 signaling mediating cross-talk between innate immune cells and neurons[12]. Additional mechanisms include:
The MEKK6-p38 pathway is activated in ALS models and patient tissue[14]:
MEKK6 plays a critical role in neuroinflammatory responses in the brain[15]:
MEKK6 is expressed throughout the human brain with cell-type specific patterns[2:1]:
The MEKK6-p38 pathway is an attractive therapeutic target for neurodegenerative diseases because:
| Strategy | Agent Type | Development Stage | Challenges |
|---|---|---|---|
| p38 MAPK inhibitors | Small molecules | Clinical trials | CNS penetration, toxicity |
| MEKK6 inhibitors | Small molecules | Preclinical | Specificity, brain delivery |
| MKK3/6 inhibitors | Small molecules | Preclinical | Isoform selectivity |
| Natural compounds | Polyphenols | Research | Bioavailability |
Despite therapeutic potential, several challenges remain:
Genetic studies have examined MEKK6 variants in neurodegenerative diseases[8:1]:
The MEKK6-p38 pathway represents a potential biomarker target for neurodegenerative diseases:
Several clinical trials have targeted the p38 pathway in neurodegenerative diseases:
| Trial Phase | Compound | Target Indication | Outcome |
|---|---|---|---|
| Phase I | PH-797804 | RA/Safety | Completed |
| Phase II | SB-681323 | COPD | Mixed results |
| Preclinical | MEKK6i | PD/AD | Ongoing |
| Preclinical | p38i + NAC | AD | Neuroprotection[9:1] |
Key lessons from past trials include the need for brain-penetrant compounds and patient selection based on biomarkers. Recent studies have demonstrated that combinatorial approaches targeting MEKK6-p38 signaling combined with antioxidant therapies show enhanced neuroprotection in preclinical models[9:2].
Future clinical trials may benefit from:
Multiple animal models have been used to study MEKK6 function:
| Model | Key Phenotypes | Relevance |
|---|---|---|
| MEKK6−/− | Developmental lethality, cardiac defects | Development studies |
| Neuron-specific MEKK6−/− | Altered stress response | Neuroprotection studies |
| MEKK6 transgenic | Neurodegeneration phenotypes | Disease modeling |
| Model Type | Applications | Advantages |
|---|---|---|
| Primary neuron cultures | PD/AD modeling | Direct relevance to neurons |
| Induced neurons (iPSC) | Disease modeling | Patient-specific genetics |
| Astrocyte cultures | Neuroinflammation | Glial contributions |
| Microglial cultures | Immune responses | Inflammation studies |
| Organoids | 3D modeling | Developmental studies |
| Species | Gene Name | Amino Acids | Key Features |
|---|---|---|---|
| Human | MAP3K6 | 372 | Full-length kinase |
| Mouse | Map3k6 | 371 | 95% identity |
| Rat | Map3k6 | 370 | 94% identity |
| Zebrafish | map3k6 | 368 | Functional conservation |
| Drosophila | dMEKK6 | 412 | Lost in some insects |
| C. elegans | kgk-1 | 356 | Functional ortholog |
The conservation of MEKK6 across species underscores its fundamental role in stress signaling. Knockout mice with targeted deletion of Map3k6 show embryonic or perinatal lethality with multiple developmental defects, demonstrating essential functions in development.
Several key questions remain about MEKK6 in neurodegeneration:
Matsumoto S, et al. MAP3K6 (MEKK6) is required for endothelial cell survival through p38-dependent signaling. Experimental Cell Research. 2005. ↩︎
Farrance ML, et al. Expression of MEKK6 in human brain. Neuroscience Letters. 2007. ↩︎ ↩︎
Xia Y, et al. MEKK6 specifically activates p38 MAPK isoforms. Journal of Biological Chemistry. 2000. ↩︎ ↩︎ ↩︎
Thalhamer J, et al. MEKK3 and MEKK6 form a novel signaling complex. Journal of Biological Chemistry. 2001. ↩︎ ↩︎
Yang R, et al. p38 MAPK isoforms in neurodegeneration. Ageing Research Reviews. 2023. ↩︎
Nakagawa H, et al. p38 MAPK in Parkinson's disease models. Journal of Neuroscience Research. 2005. ↩︎
Wang J, et al. MEKK6 mediates alpha-syn toxicity. Neurobiology of Disease. 2019. ↩︎
Zhang L, et al. MEKK6 genetic variants in neurodegeneration. Neuroscience Letters. 2020. ↩︎ ↩︎
Liu X, et al. MEKK6/p38 signaling in oxidative stress-induced neuronal death. Cell Death & Disease. 2025. ↩︎ ↩︎ ↩︎
Park J, et al. Targeting MEKK6-p38 axis in Parkinson's disease models. NPJ Parkinson's Disease. 2025. ↩︎
Kim EK, et al. MEKK6 in Alzheimer's disease. Journal of Neuroscience Research. 2009. ↩︎
Wang H, et al. MEKK6 regulates neuroinflammation via NF-κB cross-talk. Cell Death Discovery. 2024. ↩︎
Song G, et al. MEKK6 in tau phosphorylation. Journal of Neurochemistry. 2013. ↩︎
Ha HY, et al. MEKK6 in ALS models. Experimental Neurology. 2018. ↩︎
Chen L, et al. MEKK6 and neuroinflammaging. Journal of Neuroinflammation. 2024. ↩︎